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Uncontrolled generation of nitric 
oxide (NO) by inducible nitric-oxide 
synthase (iNOS) can cause damage to host 
cells and inflammation, two undesirable 
events for virus spreading. We here 
explored the role of A238L, a viral NFκB 
and NFAT inhibitor, in the regulation of 
iNOS transcription in murine 
macrophages. NO production and iNOS 
mRNA and protein levels as well as iNOS 
promoter activity after LPS/IFN-γ 
treatment were down-regulated in Raw 
264.7 cells stably expressing the viral 
protein. Overexpression of p300, but not of 
a histone acetyl transferase (HAT) 
defective mutant, reverted the A238L-
mediated inhibition of both basal and 
LPS/IFN-γ-induced iNOS promoter 
activity. Following stimulation with LPS/ 
IFN-γ, p65 and p300 interaction was 
abolished in Raw-A238L cells. Expression 
of A238L also inhibited p65/relA and p300 
binding to distal NFκB sequence of the 
iNOS promoter, together with p65 
acetylation. Finally, A238L abrogated 
p300 transactivation mediated by a GAL4-
p300 construction. These results provide 
evidence for an unique viral mechanism 
involved in transcriptional regulation of 
iNOS gene expression. 
 
Keywords: Inducible nitric oxide synthase 
(iNOS); p65; p300; A238L; African swine 
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INTRODUCTION 
 
The generation of NO from oxidation 
of L-arginine (to give citrulline and NO) is 
catalyzed by three distinct members of a 
nitric oxide synthase (NOS) family. They are 
either constitutively expressed in neurons 
(nNOS/NOSI) and endothelial cells 
(eNOS/NOSIII) or induced (iNOS/NOSII) by 
endotoxin and/or pro-inflammatory cytokines 
such as IL-1, TNF-α, and IFN-γ mainly in 
macrophages (1,2).  
The sequences of cloned iNOS 
promoters of  all species investigated so far 
exhibit homologies to binding sites for 
numerous transcription factors known to be 
involved in the LPS/cytokine-mediated 
induction of transcription (3-8). The 5'-
flanking region of murine iNOS gene 
contains two clusters of cis-acting regulatory 
elements that are essential for iNOS 
transcription; the proximal cluster is required 
for LPS-induced and the distal cluster is 
essential for IFN-γ-induced activation. Each 
cluster contains a NFκB recognition site, 
called distal (d-NFκB) and proximal (p-
NFκB) sites (5,7). Coactivators that are 
involved in iNOS promoter activation have 
been recently reported (9), showing the 
binding of p300 to iNOS promoter region and 
demonstrating that p300 overexpression 
increases LPS/IFN-γ induced iNOS promoter 
activity. 
Although much is known about the 
mechanisms of iNOS induction by viral 
infections, few transcriptional repression 
mechanisms developed by viruses have been 
described. Thus, it has been demonstrated 
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that E1A, a viral gene able to control p300 
activation  (10-12), when overexpressed in 
murine macrophages, suppressed iNOS 
activation induced by LPS/IFN-γ, indicating 
that p300 is essential for iNOS promoter 
activity in these cells. p300 is a member of a 
family of transcriptional coactivator 
molecules with distinct functional domains, 
that have been shown to interact with E1A  
and several other viral proteins such as 
simian virus 40 large T antigen  and herpes 
virus E6 and E7.  
The African swine fever virus 
(ASFV)  protein A238L has been described 
to inhibit the activation of the NFκB and 
NFAT transcription factors, both when 
expressed in Jurkat cells or during ASFV 
infection (13,14). In previous reports, we 
have also shown that A238L is thus able to 
down-regulate the transcriptional activation 
of immunomodulatory genes, such as 
cyclooxygenase-2 (COX-2) and tumor 
necrosis factor alpha (TNF-α),  by a 
mechanism involving the control of 
CBP/p300 activation (15,16).  
We describe here that A238L 
abrogates the stimulating effect of combined 
LPS/IFN-γ on iNOS promoter in Raw 264.7 
cells stably expressing the viral protein. 
In order to investigate the molecular 
mechanism by which A238L regulates iNOS 
promoter activity, we have explored the 
iNOS promoter sequences required for the 
transcriptional inhibition of iNOS in Raw-
A238L stably expressing cells, after 
LPS/IFN-γ stimulation. Using different 
specific site mutant constructions of the 
promoter, containing non functional IRF or 
GAS recognition sites, we have demonstrated 
that A238L expression decreased the 
transcription driven by p(iNOS)m-luc, 
p(iNOS)IRFmut-luc and p(iNOS)GASmut-
luc promoter constructs, indicating that 
NFκB sites seem to be essential for the 
inhibition induced by the viral protein. Our 
results also show that A238L prevents the 
enhancement of iNOS promoter activity 
mediated by p300 overexpression, as well as 
the LPS/IFN-γ increased p300 interaction 
with promoter-bound NFκB-p65. Finally, we 
also provide evidence that A238L impairs the 
p300 transactivation, thereby decreasing 
p300-mediated acetylation of the p65 subunit. 
 Taken together, these results 
represent a new and sophisticated viral 
mechanism to regulate NO production.   
 
 
EXPERIMENTAL PROCEDURES 
 
Cell culture, viruses and reagents-
The mouse macrophage cell line Raw 264.7 
was obtained from the ATCC and cultured in 
RPMI 1640 medium supplemented with 5% 
fetal bovine serum, 2 mM L-glutamine, 100 
U of gentamicin per ml and non essential 
amino acids. Cells were grown at 37ºC in 7% 
CO2 in air saturated with water vapor. Raw 
cells were stimulated by lipopolysaccharide 
(LPS, Sigma-Aldrich) at 1 µg/ml and gamma 
interpheron (IFN-γ, Peprotech) at 200 U/ml 
(LPS/IFN-γ). Generation of A238L stably 
expressing Raw 264.7 cells was done using 
the same protocol described in (16) for Jurkat 
T cells. These cellular lines were named 
Raw-pcDNA and Raw-A238L. 
 
mRNA analysis-Total RNA was 
prepared from Raw-pcDNA or Raw-A238L 
by the TRIzol reagent RNA protocol 
(Invitrogen). Total RNA (1 µg) was reverse 
transcribed into cDNA by the RevertAid First 
Strand cDNA synthesis kit (MBI Fermentas), 
and used for PCR amplification with the 
addition of Taq DNA polymerase (Roche) 
following the manufacturer’s instructions. 
Specific primers used in PCR reactions were 
murine iNOS (forward: 5’-GAGAGATCCG-
ATTTAGAGTCT-3’ and reverse: 5’-GCAG-
ATTCTGCTGGGATTTCA-3’), murine β-
actin (forward: 5’-CTCT-TTGATGTCACG-
CACGATTTC-3’ and reverse: 5’-GTGGGC-
CGCTCTAGGCACCAA-3’), and viral 
A238L (forward: 5’-CGCGCGTCTAGATT-
ACTTTCCATACTTGTT-3’ and reverse: 5’-
GCGCGCAAGCTTATGGAACACATGTTT
CCA-3’). The PCR reactions were performed 
by 30 cycles of denaturation at 94ºC for 1 
min, annealing at 52ºC for 1 min, and 
extension at 72ºC for 1 min. Amplified 
cDNAs were separated by agarose gel 
electrophoresis. 
 
Western blot analysis-Cytosolic and 
nuclear extracts from Raw-pcDNA and Raw-
A238L cells unstimulated or stimulated with 
LPS/IFN-γ, were prepared using the same 
protocol described previously (16) for Jurkat 
 3
T cells. To prepare whole-cell extracts, Raw-
pcDNA and Raw-A238L cells unstimulated 
or stimulated with LPS/IFN-γ were washed 
twice with PBS and lysed in radio 
immunolabeling protein assay (RIPA) buffer 
containing 50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1% NP-40 and 0.25% Na-
deoxycholate, and supplemented with 
protease inhibitor cocktail tablets (Roche). In 
each case, protein concentration was 
determined by the bicinchoninic acid (BCA) 
spectrophotometric method (Pierce). Cell 
lysates (30 µg of protein) were fractionated 
by SDS-PAGE, electrophoretically 
transferred to an Immobilon extra membrane 
(Millipore), and the separated proteins 
reacted with specific primary antibodies 
raised against NFκB-p50 (sc-114, Santa Cruz 
Biotechnology), NFκB-p65 (sc-109, Santa 
Cruz Biotechnology), p300 (sc-584, Santa 
Cruz Biotechnology), iNOS (AB1631, 
Chemicon), β-actin (AC-15, Sigma), and 
Acetylated lysine (Ac-K-103, Cell 
Signalling). Membranes were exposed to 
horseradish peroxidase-conjugated secondary 
antibodies (Amersham Biosciences), 
followed by chemiluminescence (ECL, 
Amersham Biosciences) detection by 
autoradiography. Densitometric analysis was 
performed by using TINA 2.0 software. 
 
Quantitation of nitric oxide in culture 
supernatants-Supernatants of Raw-pcDNA 
and Raw-A238L unstimulated or stimulated 
with LPS/IFN-γ were recovered at the 
indicated post-stimulation times. The amount 
of NO in the culture medium was determined 
by using the Griess Reagent System 
(Promega) following the manufacturer’s 
instructions. Briefly, 100 µl of culture 
supernatant were added to an equal volume of 
Griess reagent (0.1% N-(1-
naphthylenediamine) dihydrochloride plus 
1% sulphanilamide in 5% H3PO4), and A540 
was measured after a 10 min incubation in 
the dark. NO concentration of test samples 
was calculated by comparison against a 
sodium nitrite standard curve. 
 
Plasmid constructs-Murine iNOS 
promoter construct containing the full-length 
promoter sequence fused to firefly luciferase 
reporter gene, named p(iNOS)m-luc was 
generated by Sal I restriction of iNOS 
promoter (-1584/+161) from pUP1 plasmid, a 
generous gift from Dr. Santiago Lamas 
(Fundación Centro Nacional de 
Investigaciones Cardiovasculares Carlos III 
(CNIC), 28029, Madrid, Spain) and cloning 
in pGL3-basic plasmid (Promega). The iNOS 
promoter reporter constructs with mutated 
GAS site, named p(iNOS)GASmut-luc, or 
with mutated IRF site, named 
p(iNOS)IRFmut-luc, were generated by using 
Quick-Change Site-Directed Mutagenesis Kit 
(Stratagene), using the following 
oligonucleotides: 5’-CCCTCTCTCTGTTTG-
TTCCTTggCCCCTAcCACTGTCAATATT
TCAC-3’ and its complementary for GASmut 
construction, or 5’-CCCCTAACACTGTCA-
ATATggCACggTCATAATGGAAAATTCC
ATGCC-3’ and its complementary for 
IRFmut construction. The pcDNA-A238L 
expression plasmid was generated as 
described (16). The pRC-CMV-cRel 
expression plasmid, which overexpresses the 
NFκB-p50 subunit, was generated as 
described (17). The pcDNA-p65 expression 
plasmid was a generous gift from Dr. José 
Alcamí (Unidad de Inmunopatalogía, Centro 
Nacional de Microbiología, Instituto de Salud 
Carlos III, 28220-Majadahonda, Madrid, 
Spain). The GAL4-luciferase construct 
(pGAL4-Luc) contains five GAL4 DNA 
consensus binding sites derived from the 
yeast GAL4 gene fused to luciferase reporter 
gene (18). The pGAL4-p65 construct has the 
yeast GAL4 DNA binding domain fused to 
the carboxy-terminal transactivation domain 
of p65, and was generated as described (19). 
The GAL4-p300 construct was a generous 
gift from Dr. Neil Perkins (School of Life 
Sciences, Division of Gene Regulation and 
Expression, University of Dundee, Dundee, 
Scotland, United Kingdom), and generated as 
described (20). The p300 wild type 
expression plasmid pCl-p300 and its histone 
acetyl transferase (HAT) deletion mutant, 
pCl-p300∆HAT, was a generous gift from 
Dr. Joan Boyes (Institute of Cancer Research,  
London SW3 6JB, UK) and generated as 
described (21). 
 
Transfection and luciferase assays-
Raw-pcDNA and Raw-A238L cells were 
transfected with 250 ng of specific reporter 
plasmids per 106 cells using the 
LipofectAMINE Plus Reagent (Invitrogen) 
according to the manufacturer’s instructions 
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and mixing in Opti-MEM (Invitrogen) in a 6-
well plate. In cotransfection assays, 0.1-1.6 
µg of the corresponding expression plasmid 
per 106 cells were added. The cells were 
incubated for 4 h, washed, incubated in 
serum-free medium for 24 h, and treated with 
or without LPS/IFN-γ. As a transfection 
control for luciferase assays, the Renilla 
luciferase control plasmid pRL-TK (Promega) 
was cotransfected in all of the experiments. 
At the indicated post-stimulation times, cells 
were lysed with 200 µl of Cell Culture Lysis 
Reagent (Promega) and microcentrifuged at 
full speed for 5 min at 4ºC, and 20 µl of each 
supernatant was used to determine Firefly 
and Renilla luciferase activity in a Monolight 
2010 luminometer (Analytical Luminescence 
Laboratory) using Dual Luciferase Assay 
System (Promega). Transfections were 
normalized to Renilla luciferase activity and 
results were expressed as the relative 
luminescence units after normalization of 
protein concentration determined by the BCA 
method, as indicated in the figure legends. 
Transfection experiments were performed in 
triplicate, and the data presented as the mean 
of the relative luciferase units (RLU) (mean ± 
S.D.). 
 
In vitro DNA-protein binding assay-
Binding of p50, p65 and p300 proteins to 
NFκB sequences in the iNOS promoter DNA 
was analyzed by a DNA-protein binding 
assay, by using streptavidin-coated beads to 
bind biotinylated DNA probe, which was 
incubated with nuclear extract proteins. 
Biotine-labeled double-stranded 
oligonucleotide probes corresponding to 
murine distal NFκB sequence (5’/biotine/-
CTAGGGGGATTT-TCCCTCTC-3’), or 
murine proximal NFκB sequence 
(5’/biotine/-AACTGGGGACTCTCCCTTT-
G-3’), or a non-relevant DNA sequence 
(5’/biotine/-TTACCAACTGAGCCATCTC-
C-3’) were synthesized by Isogen. The 
binding assay was performed by mixing 500 
µg of nuclear extract proteins (obtained as 
described above) from Raw-pcDNA or Raw-
A238L cells unstimulated or stimulated with 
LPS/IFN-γ, 5 µg of biotinylated probe, and 50 
µl of 4% streptavidin beaded agarose (Sigma) 
with 70% slurry. The mixture was incubated 
at room temperature for 1 h with shaking. 
Beads were then pelleted and washed three 
times with ice-cold PBS. The bound proteins 
were eluted in loading buffer and separated 
by 4–15% PAGE, followed by Western blot 
analysis probed with antibodies against p50 
(sc-114, Santa Cruz Biotechnology), p65 (sc-
109, Santa Cruz Biotechnology) or p300 (sc-
584, Santa Cruz Biotechnology). 
Coimmunoprecipitation-.Nuclear 
extracts were prepared from 80–90% 
confluent Raw-pcDNA and Raw-A238L cells 
treated with or without LPS/IFN-γ for 6 h and 
their protein concentrations were determined 
as described above. Nuclear extracts were 
incubated with a specific p65 antibody (sc-
109, Santa Cruz Biotechnology) or a rabbit 
preimmune normal IgG as a negative control, 
at a final concentration of 4 µg/ml. The 
samples were incubated at 4°C overnight. 
Protein A/G-sepharose beads (Sigma) were 
added, incubated for 3 h at 4ºC, and 
centrifuged. The beads were washed three 
times with wash buffer (50 mM Tris-HCl pH 
8, 150 mM NaCl, 1 mM EDTA, and 0.5% 
Nonidet P-40). The immunoprecipitates were 
mixed with SDS loading buffer and analyzed 
by 4–15% SDS-PAGE followed by Western 
blotting using specific antibodies against p65 
and p300.  
Acetylation of p65-NFκB-p65 in 
nuclear extracts was immunoprecipitated 
with a specific antibody against p65 (sc-109, 
Santa Cruz Biotechnology) or a rabbit 
preimmune normal IgG as a negative control, 
at a final concentration of 4 µg/ml, as 
described above. The immunoprecipitates 
were collected by using protein A/G-
sepharose beads (Sigma). The beads were 
washed three times with wash buffer, as 
described above. The immunoprecipitates 
were mixed with SDS loading buffer and 
analyzed by 4-15% SDS-PAGE. Acetylated 
p65 was detected by Western blot using an 
antibody against acetylated lysine (Ac-K-103, 
Cell Signaling Technology). 
 
 
RESULTS 
 
A238L Down-regulates iNOS Gene 
Expression and NO Synthesis. iNOS 
transcription is regulated by several 
transcription factors such as NFκB, NF-IL6, 
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Oct-1, AP-1, C/EBP, CREB, IRF-1, SRF and 
STAT-1α. Since A238L has been described 
as an inhibitor of some of these transcription 
factors (13-16), we have explored the 
possibility that the viral protein could inhibit 
iNOS activity. To investigate the role of the 
viral protein in the control of iNOS 
transcription, we have generated Raw 264.7 
cells that stably express the A238L gene by 
transfection with pcDNA-A238L, followed 
by selection using G-418 as described under 
Experimental Procedures. Fig. 1A shows the 
expression of specific mRNA for A238L in 
Raw 264.7 cells stably expressing A238L that 
is absent in Raw-pcDNA control cells. It has 
been previously reported that macrophages 
activation induced by LPS/IFN-γ increases 
iNOS mRNA levels. In agreement with these 
data, iNOS mRNA was increased in cells 
transfected with the empty pcDNA vector 
upon treatment with LPS/IFN-γ. More 
interestingly, we found lower levels of iNOS 
transcript in cells expressing A238L after 
stimulation with LPS/IFN-γ (Fig. 1A), 
indicating that the viral protein is able to 
regulate iNOS expression. To address 
whether iNOS mRNA inhibition was 
paralleled by iNOS protein decrease, we 
performed Western blot analysis with cellular 
extracts from Raw-pcDNA or Raw-A238L, 
using a specific antibody against iNOS 
protein. As expected, iNOS protein levels 
were clearly diminished after LPS/IFN-γ  
activation in Raw-A238L as compared to 
control cells (Fig. 1B), showing a similar 
inhibition to that obtained in mRNA analysis.  
NO production in the form of nitrite 
was also determined in culture supernatants 
from Raw-pcDNA or Raw-A238L after 
stimulation with LPS/IFN-γ. Unstimulated 
cells produced undetectable levels of NO2-, 
while, after stimulation, the amounts of nitrite 
secreted in culture supernatants differed 
considerably depending on the A238L 
expression. Raw-pcDNA cells secreted 
significant NO2- amounts upon LPS/IFN-γ 
treatment, whereas the amounts of nitrite 
detected in supernatants from Raw-A238L 
were lower (approximately 50%) from 12 h 
post-stimulation, showing a parallelism with 
the down-regulation of iNOS mRNA and 
protein expression (Fig. 1C). 
 
NFκB specific sites are required for 
A238L inhibition of iNOS promoter activity 
after stimulation with LPS/IFN-γ.  
Considering the critical importance of NFκB 
in regulating iNOS transcription, we 
hypothesized that A238L, that has been 
previously described as a viral IκB 
homologue which inhibits NFκB activation 
(14,15), might have a modulatory role for 
transcriptional repression of iNOS gene 
expression. To test this hypothesis, Raw-
pcDNA or Raw-A238L cells were transfected 
with the plasmid p(iNOS)m-luc, which 
contains the luciferase reporter gene under 
the control of the full length sequence of the 
mouse iNOS promoter. The 5'-flanking 
region of murine iNOS gene contains two 
clusters of cis-acting regulatory elements that 
are essential for iNOS transcription of which 
the proximal cluster is required for LPS-
induced and the distal cluster for IFN-γ-
induced activation. It is also known that 
LPS/IFN-γ synergistically activate iNOS 
promoter by stimulating the binding of 
several transcription factors, mainly NFκB, 
IFN-regulatory factor-1 (IRF-1), and C/EBP 
to their respective cognitive sites in these two 
clusters of regulatory elements (5,7).    
As shown in Fig. 2A, and in parallel 
with the above described down regulation of 
iNOS mRNA levels, ectopic A238L 
expression strongly decreased the 
transcription driven by the p(iNOS)m-luc 
construction after stimulation with LPS/IFN-
γ. 
In order to investigate the molecular 
mechanism by which A238L regulates iNOS 
promoter activity, we have explored the 
iNOS promoter sequences required for the 
transcriptional inhibition of iNOS in Raw-
A238L. Raw-pcDNA or Raw-A238L cells 
were transfected with two different 
constructions of the promoter, 
p(iNOS)IRFmut-luc and p(iNOS)GASmut-
luc. Both constructions are identical to the 
plasmid p(iNOS)m-luc, except for one 
mutation either in the IRF-E element or in the 
GAS element in the distal region of the 
promoter, as described under Experimental 
procedures. Sixteen hours after transfection 
cells were cultured in the absence or presence 
of LPS/IFN-γ for 6 h and assayed for 
luciferase activity. The results presented in 
Fig. 2B show that inducibilty of 
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p(iNOS)IRFmut-luc and p(iNOS)GASmut-
luc mutated promoters was significantly 
decreased. However, A238L expression 
decreased about 50% the transcription driven 
by those promoters to similar extent as with 
the full p(iNOS)m-luc, promoter. Those 
results indicate that those sites are 
dispensable for A238L inhibition and point 
out to NFκB sites, essential for 
transcriptional activation of the iNOS murine 
gene (22) as the target. 
 
p300 Overexpresion Reverts the 
A238L-mediated Inhibition of the iNOS 
Promoter Activity and iNOS Protein 
Synthesis. p300 plays a major role as 
coactivator for multiple transcription factors 
in the induction of several pro-inflammatory 
genes such as TNF-α, COX-2, IFN-β and 
iNOS by viruses and LPS/IFN-γ (9,23-25). 
Binding of p300 to iNOS promoter region 
and increased iNOS gene transcription by 
p300 overexpression has been recently 
described (9). On the other hand, we have 
previously shown that CBP/p300 
overexpression reverts the A238L-mediated 
inhibition of the pTNF(-120)luc promoter 
activity. To characterize a putative 
involvement of transcriptional coactivator 
p300 in the iNOS promoter activity down-
regulation induced by the viral protein, we 
have cotransfected increasing amounts of 
expression plasmid for p300 (pCl-p300 wt), 
together with p(iNOS)m-luc into Raw-
pcDNA and Raw-A238L cells. Sixteen hours 
after transfection, the cells were cultured in 
the absence or presence of LPS/IFN-γ during 
6 h and assayed for luciferase activity. As 
shown in Fig. 3A, a dose response induction 
of iNOS promoter activity was shown by 
overexpression of p300 in Raw-pcDNA cells 
after stimulation with LPS/IFN-γ. More 
interestingly, p300 rescued the activity of the 
promoter in a dose-dependent manner in 
Raw-A238L cells, indicating the involvement 
of the coactivator in the inhibition of iNOS 
expression by A238L. Transfection of pCl-
p300∆HAT, a histone acetyl transferase 
(HAT) deletion mutant of p300, in Raw-
pcDNA or Raw-A238L, did not have 
costimulatory activity and did not reverted 
the A238L inhibition, consistent with the 
involvement of p300 HAT in iNOS 
transactivation and suggesting that this 
domain prevents A238L down regulation 
(Fig. 3A). To confirm the involvement of 
p300 in the inhibitory mechanism induced by 
the viral protein, we performed Western blot 
analysis with cellular extracts from Raw-
pcDNA or Raw-A238L, previously 
transfected with pCl-p300 or pCl-p300∆HAT 
(Fig. 3B). Using a specific antibody against 
iNOS, it could be detected a recovery of 
iNOS protein levels after overexpression of 
wild type p300, whereas no effect was 
observed after expression of p300∆HAT. Fig. 
3B also shows that the levels of p300 protein, 
that could be detected both in Raw-pcDNA 
and Raw-A238L resting cells, were not 
increased after treatment with LPS/IFN-γ. 
Taken together, these results indicate that 
A238L-mediated iNOS inhibition is 
accomplished by modulation of p300 
transcriptional coactivator. 
 
A238L Displaces p65 and p300 from 
Distal NFκB Specific DNA Sequence in the 
iNOS Promoter. To further investigate the 
mechanism by which A238L controls the 
activity of the iNOS promoter, we have 
carried out DNA-protein binding experiments 
using biotinylated distal (d-NFκB) and 
proximal (p-NFκB) probes. To achieve this, 
the biotinylated DNA probes were incubated 
with nuclear extracts from Raw-pcDNA or 
Raw-A238L cells treated or not with 
LPS/IFN-γ, and the complex was pulled 
down with streptavidin-agarose beads, as 
described in Experimental Procedures. 
Finally, the proteins in the complex were 
analyzed by Western blotting using 
antibodies against p300, NFκB-p65 and 
NFκB-p50. As shown in Fig. 4A, p300, p65 
and p50 were present in similar extent in 
whole nuclear extracts from either Raw-
pcDNA or Raw-A238L and its binding in 
control cells increased, after LPS/IFN-γ 
stimulation. This increase was evident for 
p50 in both sites, but also for p65 and p300, 
to the d-NFκB site. Interestingly, the results 
of the pull down assay showed that, while 
p300, p65 and p50 were bound to the d-
NFκB in control cells, the levels of both p300 
and p65 bound to this site were significantly 
lower in the case of cells expressing A238L, 
indicating that the viral protein partially 
displaces or prevents the binding of p300 and 
p65 from this specific site in the iNOS 
promoter. On the other hand, these results 
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also suggest that A238L inhibits iNOS 
promoter activity by displacing p300 and p65 
from the d-NFκB specific site, whereas the 
second NFκB site in the iNOS promoter, the 
p-NFκB, would be involved in a lesser, if 
any, degree in the control of iNOS activity 
induced by the viral product. It is interesting 
to note that p50 remains bound to d-NFκB in 
Raw-A238L cells, revealing that binding of 
this subunit to the promoter seems not to be 
affected by the presence of the viral protein, 
suggesting that p50 is not involved in the 
mechanism of inhibition induced by A238L 
to control iNOS transcription. To confirm this 
last hypothesis, and to further demonstrate 
the involvement of p65 in the inhibition 
induced by A238L, Raw-pcDNA or Raw-
A238L cells were transiently transfected with 
the p(iNOS)m-luc reporter plasmid together 
with increasing doses (from 0 to 1.6 µg of 
DNA/106 cells) of the expression plasmid 
pRC-CMV-cRel to overexpress the p50 
subunit of NFκB transcription factor or 
pCMV-p65 to overexpress the p65 subunit. 
Sixteen hours after transfection, the cells 
were cultured in the absence or presence of 
LPS/IFN-γ for 6 h and assayed for luciferase 
activity. The results clearly showed that p65 
overexpression recovered the inhibition of 
iNOS promoter induced by A238L, whereas 
the A238L-mediated inhibition of the 
promoter was not affected by the expression 
of similar amounts of p50.  
 
A238L Interferes with the Interaction 
of p65 and p300. Since A238L was shown to 
interact with p65 during ASFV infection (14), 
and considering that the p65 subunit of NFκB 
recruits p300 to its transcriptional activation 
complex through the C/H1 domain (26), we 
investigated whether the mechanism whereby 
A238L suppresses the transcriptional 
activation of the iNOS/NFκB signal 
transduction pathway involved direct 
competition for binding to p300. To achieve 
this, we prepared nuclear extracts from 
resting and LPS/IFN-γ-stimulated Raw-
pcDNA and Raw-A238L cells, and the 
interaction between p65 and endogenous 
p300 was examined by immunoprecipitation 
with specific antibodies for p65 or control 
serum. The presence of p300 and p65 in the 
immunoprecipitate was analyzed by Western 
blot. The results shown in Fig. 5 indicate that 
p300 complexed with NFκB-p65 was 
increased by LPS/IFN-γ treatment as 
previously described (9), but, more 
important, the presence of A238L prevented 
this interaction. A control rabbit preimmune 
IgG did not precipitate a p300-containing 
complex. 
Thus, A238L abrogates the binding of p300 
to p65 in the nucleus both at basal and 
LPS/IFN-γ-stimulated cellular states, 
suggesting that iNOS transcriptional 
inhibition by the viral protein is dependent on 
its ability to compete with p65 for binding to 
p300 coactivator.  
 
Inhibition of p65 Acetylation by 
A238L. We have shown above that the 
increase of the iNOS promoter activity by 
overexpression of wt p300 in Raw-pcDNA 
was inhibited in Raw-A238L cells, and in 
parallel, that p65 and p300 binding to the 
iNOS promoter distal NFκB probe was 
interfered by A238L in resting and LPS/IFN-
γ-treated cells. Activation of iNOS promoter 
has been described to be regulated by p300-
mediated acetylation of NFκB-p50 (9). To 
determine whether the mechanism by which 
A238L inhibits the iNOS promoter activity 
might be regulated by acetylation, we 
prepared nuclear extracts from resting and 
LPS/IFN-γ-treated Raw-pcDNA and Raw-
A238L cells, immunoprecipitated the nuclear 
extract proteins with an antibody against p65, 
and acetylation in the immunoprecipitate was 
detected by Western blot with an anti acetyl-
lysine antibody. Acetylated p65 was 
detectable at basal cell state, and increased by 
about 3-fold in Raw-pcDNA LPS/IFN-γ- 
treated cells, whereas the expression of the 
viral protein resulted in strong reduction of 
acetylated p65 both at basal state and in 
LPS/IFN-γ-stimulated Raw-A238L cells (Fig. 
6). These results indicate a relationship 
between p65 acetylation and A238L 
regulation of the iNOS promoter. 
 
A238L Down-regulates the 
Transactivation Function of p65. Regulation 
of NFκB following stimulation with 
LPS/IFN-γ occurs via activation of at least 
two pathways. The best characterized of these 
regulates the release of NFκB from IκBα and 
the subsequent translocation of NFκB to the 
nucleus. However, this is not sufficient to 
 8
activate NFκB-dependent gene transcription. 
The second pathway, which involves post-
translational modifications, regulates the 
transactivating ability of the p65 subunit of 
NFκB. We have previously described that 
A238L, a viral IκBα homologue, does not 
control the nuclear translocation of NFκB but 
regulates the transactivation of this 
transcription factor in Jurkat cells (15). Due 
to the fact that A238L interferes with the 
interaction of p65 and p300 and inhibits p65 
acetylation when overexpressed in Raw 264.7 
cells, it is plausible that the viral protein 
might inhibit p65 transactivation as a part of 
the mechanism used in the down-regulation 
of iNOS promoter in mouse macrophages. To 
address this question, we used a plasmid 
encoding the GAL4-p65 fusion protein, 
where the DNA-binding domain of GAL4 
has been joined to the transactivation domain 
of RelA/p65. Raw-pcDNA or Raw-A238L 
were cotransfected  with the GAL4-p65 and a 
GAL4-Luc reporter, allowing us to determine 
whether the viral protein down-regulates 
iNOS gene expression by specifically 
targeting the transactivation domain of the 
RelA/p65 subunit of NFκB. Fig. 7 shows that 
in the presence of the A238L protein, the 
ability of LPS/IFN-γ to activate GAL4-p65 
was strongly inhibited in stimulated Raw 
264.7 cells. 
 
p300 Transactivation is Inhibited by 
A238L. The p300/CBP acetyltransferases 
regulate different functions of NFκB, 
including transcriptional activation, by 
targeting distinct lysine residues of RelA/p65 
(27-30). Previously we have shown that the 
ability of p300 to coactivate NFκB is strongly 
down-regulated by expression of A238L, and 
that overexpression of p65 could recover the 
inhibition of TNF-α promoter (15). However, 
the need to recruit p300 to the promoter 
through NFκB, which itself is a regulated 
event (26), made difficult to conclude that the 
effect of A238L was directly on p300 itself. 
To enable the analysis of this possibility, we 
have used in the present work the plasmid 
GAL4-p300. This construction contains the 
complete p300 sequence fused to the GAL4 
DNA binding domain (20). By using this 
approach, we also overcome any side effects 
from endogenous p300, because iNOS 
promoter is targeted through GAL4. GAL4-
p300 was then cotransfected with the GAL4-
luc reporter plasmid into Raw-pcDNA and 
Raw-A238L cells. As expected, GAL4-p300 
stimulated luciferase activity after LPS/IFN-γ 
in Raw-pcDNA cells (Fig. 8). Interestingly, 
the presence of A238L resulted in a strong 
down-regulation of p300 transactivation, 
while GAL4 alone was unaffected (data not 
shown). These results confirmed that the 
transcriptional activity of p300 is specifically 
inhibited by A238L.  
 
 
DISCUSSION 
 
Previously, we reported that the ASFV 
protein A238L plays a critical role in 
mediating inhibition of COX-2 and TNF-α 
gene transcription, and several functional 
NFκB, NFAT and AP-1/jun response 
elements in the human promoters of these 
pro-inflammatory molecules regulated by the 
viral protein have been identified (15,16). In 
addition, the inducible signal coactivators of 
transcription CBP and p300 have been 
reported to be regulated by A238L (15). 
However, no information existed as to the 
transcriptional mechanisms that govern 
repression of iNOS gene expression would be 
controlled by A238L. This is particularly 
interesting given that the regulation of the 
iNOS gene is extremely complex and 
involves the interaction of both basally 
expressed and inducible transcription factors 
with the coactivators CBP/p300, which could 
be targeted by A238L to modulate NO 
production during ASFV infection of 
macrophages, the natural target of the virus. 
The sustained high output of NO accounts for 
its anti-microbial effects against a variety of 
pathogens including viruses (31-33). Thus, 
the regulation of the iNOS promoter activity 
by A238L would be an important checkpoint 
in the virus cycle.  
An essential role of NFκB binding sites for 
the induction of iNOS promoter activity has 
been shown in murine cells (5,22). 
Furthermore, the important role of the IRF-1 
binding site (positions −913 to −923 bp) for 
the induction of the promoter has been 
reported in RAW 264.7 macrophages (34,35). 
Using two different constructions of the 
promoter containing mutations either in the 
IRF-E element or in the GAS element in the 
distal region of the promoter, we have 
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demonstrated that A238L expression 
decreased the transcription driven by 
p(iNOS)IRFmut-luc mutant and 
p(iNOS)GASmut-luc mutant promoter 
constructs in a similar level to that obtained 
when the wild type promoter p(iNOS)m-luc 
construct was used, although the inducibility 
by the mutant promoters was lower. These 
data suggest that these sequences are not 
involved in the control of the promoter by the 
virus and point out that A238L inhibits the 
iNOS expression specifically through NFκB 
sites. 
Our results also show that 
overexpression of p300 by transient 
transfection of Raw 264.7 cells elicits a 
concentration-dependent increase in iNOS 
promoter activity stimulated by LPS/IFN-γ 
that reverted the inhibition induced by the 
presence of A238L. In line with these results, 
we have also found that the overexpression of 
p300 counteracts the inhibition of iNOS 
levels mediated by A238L. These results not 
only corroborate that p300 is involved in the 
control of iNOS transcriptional activation in 
Raw 264.7 cells (9), but also that its 
enhancing effect is competed by the presence 
of A238L. Both p300 and CBP contain a 
histone acetyltransferase (HAT) enzymatic 
activity that regulates gene expression 
through acetylation of the N-terminal tails of 
histones (36). Acetylated histones are 
associated with transcriptionally active 
segments of chromatin, whereas deacetylated 
histones accumulate in transcriptionally 
repressed regions (37-39). It is noteworthy 
that the p300∆HAT deletion mutant construct 
is unable to restore the iNOS protein levels 
inhibited by the viral protein, in agreement 
with the general concept  that the core HAT 
domain is required for p300-mediated iNOS 
promoter activity and suggesting that A238L-
mediated iNOS inhibition might be related 
with the acetylase activity of p300 .  
The p300 binding and interaction 
with DNA bound NFκB subunits p65 and 
p50 at iNOS promoter has been shown to be 
enhanced by LPS/IFN-γ stimulation (9,27). 
Our results from DNA-protein binding assays 
corroborate that the binding of p300/p65/p50 
transcriptional complex to the distal NFκB 
sequence at the iNOS promoter is enhanced 
by LPS/IFN-γ stimulation. More 
interestingly, our findings also indicate that 
p65 is strongly displaced of the complex in 
Raw-A238L cells, whereas p50 binding 
seems to be not affected by the expression of 
the viral protein. This differential effect of 
both NFκB subunits was confirmed by 
overexpression of p65 or p50 subunits in 
Raw-pcDNA or Raw-A238L cells transiently 
transfected with the p(iNOS)m-luc. The 
results clearly showed that increasing doses 
of p65 , but not p50, not only induced iNOS 
promoter transcription  but more importantly 
recovered the inhibition of iNOS promoter 
induced by A238L, supporting the 
involvement of this protein in the control of 
iNOS induced by the viral protein.   
The p65 subunit of NFκB has been 
shown to recruit p300 to its transcriptional 
activation complex (26). On the other hand, 
A238L and p300 have been previously shown 
to colocalize in the nucleus of stimulated 
Vero cells (15). We have explored whether 
the mechanism whereby A238L suppresses 
the transcriptional activation of the iNOS/p65 
signal transduction pathway involves direct 
competition for binding to p300. 
Immunoprecipitation assays demonstrate that 
p300 interacts with p65 in the nucleus of 
resting cells, which was enhanced by LPS and 
IFN-γ. Importantly, we have found that 
A238L abrogates the binding of p300 and 
p65 not only at basal but also at LPS/IFN-γ-
stimulated cellular states, indicating that 
iNOS transcriptional inhibition by the viral 
protein might involve the competition with 
p65 for binding to p300 coactivator. The 
mechanism by which p300/CBP enhances 
NFκB transcriptional activity is likely multi-
factorial. In addition to modifying histones, 
p300/CBP also directly acetylates several 
transcription factors, including p65, p50, p53, 
Tat, GATA-1, MyoD, TFIIEß and E2F (40-
43). Acetylation of these factors is a critical 
step in transcriptional regulation leading to 
changes in their biological activity, such as 
alterations in DNA binding affinity, 
transcriptional activity and interaction with 
other proteins (40,42-44). In the present work 
we present a clear correlation between p65 
acetylation, p65 binding to DNA and p300 
recruitment to the distal NFκB sequence in 
the iNOS promoter in Raw-pcDNA cells 
treated with LPS/IFN-γ. Furthermore, the 
viral protein expression induces a concordant 
decrease either in p65/d-NFκB binding, 
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p300-mediated acetylation and p300-p65 
interaction in Raw-A238L cells.  
Interaction with p300 and CBP 
provides an additional level of regulation for 
certain transcription factors (27,30,45). 
Furthermore, and providing additional 
complexity, the transcriptional activities of 
p300 and CBP are themselves directly 
regulated. A number of signaling pathways, 
including p300 and/or CBP phosphorylation, 
have been demonstrated during cell 
differentiation, cell cycle progression and cell 
signaling via the protein kinase C and cyclin 
E-CdK2 pathways (46,47). Our previous 
results demonstrated that A238L, a nuclear 
viral protein that colocalizes with p300, binds 
to the CRE/κ3 complex in the TNF-α 
promoter and displaces the coactivators 
CBP/p300 to inhibit the transactivation of 
associated factors as NFAT, NFκB and c-Jun 
(15). Herein we also demonstrate that the 
viral protein inhibits the transactivation of 
p300 impairing the recruitment of this 
coactivator to the transcriptional complex in 
specific sequences of the iNOS promoter. 
Further experiments are needed to explore 
whether the mechanism used by A238L to 
inhibit the transactivation of p300 involves 
regulation in phosphorylation of this 
coactivator. 
In conclusion, the data presented here 
establish, for the first time, a new viral 
mechanism of p300 transcription coactivator 
activity down-regulation to modulate iNOS 
activation. However, future work is required 
to address the precise strategy used by this 
viral protein to achieve this effect on p300 
transactivation. A detailed understanding of 
the mechanism by which iNOS gene 
transcription is controlled by A238L in 
macrophages offers potential novel insights 
regarding the role of iNOS in several 
inflammatory pathologies. 
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FOOTNOTES 
The abbreviations used are: NO, nitric oxyde; iNOS, inducible nitric oxyde synthase; NFκB, 
nuclear factor-kappa B; NFAT, nuclear factor of activated T cells; COX-2, cyclooxygenase-2; 
TNF-α, tumor necrosis factor alpha; IκB, inhibitory proteins of the IκB family; PKC, protein 
kinase C; wt, wild type; Ac-p65, acetylated p65; ASFV, African swine fever virus; LPS, 
lipopolysaccharide; IFN-γ, gamma interferon; CBP, CREB binding protein; CREB, cAMP-
response element binding protein; AP-1, activating protein 1; Oct-1, octamer factor 1; NF-IL6, 
nuclear factor IL-6; C/EBP, CCAAT-enhancer box binding protein; IRF, interferon response 
factor; GAS, gamma-interferon activated site; SRF, serum response factor; RLU, relative 
luciferase unit; PBS, phosphate-buffered saline. 
 
 
FIGURE LEGENDS 
FIG. 1. Analysis of iNOS expression in stably expressing A238L Raw cells. A, Total RNA 
(1 µg) from Raw-pcDNA and Raw-A238L cells cultured in the absence (0 h) or presence of 1 
µg/ml of LPS plus 200 U/ml of IFN-γ (LPS/IFN-γ) was analyzed at the indicated times by RT-
PCR to measure A238L and iNOS mRNA expression. A control using specific oligonucleotides 
for β-actin is also included to rule out differences in PCR amplification. B, Western blot of 
stably expressing A238L cells (Raw-A238L) or control cells (Raw-pcDNA) cultured in the 
absence (0h) or presence of 1 µg/ml of LPS plus 200 U/ml of IFN-γ (LPS/IFN-γ). At the 
indicated times post-stimulation, whole-cell extracts were prepared, subjected to SDS-PAGE 
(30 µg of protein sample), and detected by immunoblotting with an iNOS specific antibody. A 
control of protein loading is included by β-actin blotting. C, Nitrite accumulation in the 
supernatant of stably expressing A238L cells (Raw-A238L) or control cells (Raw-pcDNA) 
cultured in the absence or presence of 1 µg/ml of LPS plus 200 U/ml of IFN-γ (LPS/IFN-γ). At 
the indicated times post-stimulation, culture supernatants were recovered and nitrite content was 
measured using Griess reagent as described under Experimental Procedures.  
 
FIG. 2. Effect of A238L upon the transcriptional activation of the iNOS promoter. A, Raw-
pcDNA (grey bars) or Raw-A238L (black bars) cells were transiently transfected with the 
p(iNOS)m-luc murine promoter construct (250 ng/106 cells) as described under Experimental 
Procedures. Sixteen hours after transfection, the cells were cultured in the absence or presence 
of 1 µg/ml of LPS (LPS) plus 200 U/ml of IFN-γ (LPS/IFN-γ). At the indicated times post-
stimulation, whole cell extracts were prepared and assayed for luciferase activity. Extracts were 
normalized to Renilla luciferase activity as described in Experimental Procedures. Results from 
triplicate assays are shown in relative light units (RLU) per µg of protein (mean ± S.D.). 
Numbers upon the bars represent the ratio between the RLU values obtained from Raw-pcDNA 
vs Raw-A238L cells in each time. B, Raw-pcDNA (grey bars) or Raw-A238L (black bars) cells 
were transiently transfected with the indicated iNOS promoter construct; complete murine 
promoter, p(iNOS)m-luc; complete promoter with the IRF site mutated, p(iNOS)IRFmut-luc; or 
complete promoter with the GAS site mutated p(iNOS)GASmut-luc; as described under 
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Experimental Procedures. Sixteen hours after transfection, the cells were cultured in the 
absence or presence of 1 µg/ml of LPS plus 200 U/ml of IFN-γ during 6 h. Whole cell extracts 
were prepared and assayed for luciferase activity. Extracts were normalized to Renilla luciferase 
activity as described in Experimental Procedures. Results from triplicate assays were used to 
estimate the fold induction values for each cellular line and promoter construct (mean ± S.D.). 
 
FIG. 3. Effect of p300 overexpression in iNOS promoter activation and iNOS protein 
levels. A, Raw-pcDNA (open bars) or Raw-A238L (shaded bars) cells were transiently 
transfected with the p(iNOS)m-luc promoter reporter plasmid and with the indicated doses 
(from 0 to 1.6 µg of DNA/106 cells) of pCl-p300 wt or p300 HAT deletion mutant (pCl-
p300∆HAT) expression plasmids. Sixteen hours after transfection, the cells were cultured in the 
absence (plain bars) or presence of 1 µg/ml of LPS plus 200 U/ml of IFN-γ (stripped bars) 
during 6 h and assayed for luciferase activity. Extracts were normalized to Renilla luciferase 
activity as described in Experimental Procedures. Results from triplicate assays are shown in 
relative light units (RLU) per µg of protein (mean ± S.D.). B, Effect of p300 wt and p300 HAT 
mutated in iNOS protein levels. The figure shows p300 and iNOS protein levels determined by 
Western blot in Raw-pcDNA and Raw-A238L cells transfected with 1.6 µg of DNA/106 cells of 
pCl-p300wt, pCl-p300∆HAT, or empty pCl plasmid as a control. Sixteen hours after 
transfection, the cells were treated (+) or not (-) with 1 µg/ml of LPS plus 200 U/ml of IFN-γ 
(LPS/IFN-γ) for 12 h, and whole cell extracts were prepared, subjected to 4-15% SDS-PAGE, 
and detected by immunoblotting with p300 and iNOS specific antibodies. A control of protein 
loading is included by β-actin blotting. The result is a representative assay from two separate 
experiments. Western blot shown has been performed using the same membrane and exposition.    
 
 FIG. 4. Effect of A238L on the binding of p50/p65 and p300 to NFκB sites in the iNOS 
promoter. A, Nuclear extracts from Raw-pcDNA and Raw-A238L cells treated (+) or not (-) 
with 1 µg/ml of LPS plus 200 U/ml of IFN-γ (LPS/IFN-γ) for 6 h were incubated with the 
indicated biotinylated probe and the complex was pulled down with streptavidin-agarose beads, 
as described under Experimental Procedures. After extensive washing, proteins in the complex 
were analyzed by Western blotting using antibodies against p300, p65 or p50. Control probe is a 
biotinylated 22-bp nonrelevant DNA sequence of murine iNOS promoter. Inputs were also 
included to show the presence of the analyzed proteins in nuclear protein extracts of Raw cells. 
B, Raw-pcDNA (open bars) or Raw-A238L (shaded bars) cells were transiently transfected with 
the p(iNOS)m-luc reporter plasmid and with the indicated doses (from 0 to 1.6 µg of DNA/106 
cells) of two different expression plasmids: pRC-CMV-cRel to overexpress the p50 subunit of 
NFκB or pCMV-p65 to overexpress the p65 subunit of NFκB transcription factor. Sixteen hours 
after transfection, the cells were cultured in the absence (plain bars) or presence of 1 µg/ml of 
LPS plus 200 U/ml of IFN-γ (LPS/IFN-γ) for 6 h (stripped bars) and assayed for luciferase 
activity. Extracts were normalized to Renilla luciferase activity as described in Experimental 
Procedures. Results from triplicate assays are shown in relative light units (RLU) per µg of 
protein (mean ± S.D.). 
 
FIG. 5. A238L inhibits the direct interaction between NFκB-p65 and p300. Nuclear extracts 
from 107 stably transfected Raw-pcDNA and Raw-A238L cells treated (+) or not (-) with 1 
µg/ml of LPS plus 200 U/ml of IFN-γ (LPS/IFN-γ) for 6 h were incubated and 
immunoprecipitated with 4 µg of rabbit polyclonal NFκB-p65 specific antibody (p65) or rabbit 
preimmune normal IgG (control IgG) as a negative control of co-immunoprecipitation, as 
described under Experimental Procedures. Immunoprecipitates were separated by 4-15% SDS-
PAGE, electrophoretically transferred to an immobilon membrane, and detected by 
immunoblotting with the same NFκB-p65 (αp65) antibody to determinate levels of p65 in the 
precipitate, or with p300 (αp300) specific antibody to detect the interaction between p65 and 
p300. The densitometric analysis shows the ratio between co-immunoprecipitated p300 amount 
and p65 precipitated amount, from three independent experiments (mean ± S.D).  
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FIG. 6. A238L inhibits the acetylation of p65 in stimulated Raw cells. Nuclear extracts from 
107 stably transfected Raw-pcDNA and Raw-A238L cells, treated (+) or not (-) with 1 µg/ml of 
LPS plus 200 U/ml of IFN-γ (LPS/IFN-γ) for 6 h, were incubated and immunoprecipitated with 
4 µg of rabbit polyclonal NFκB-p65 specific antibody (αp65), as described under Experimental 
Procedures. Immunoprecipitates were separated by 8% SDS-PAGE, electrophoretically 
transferred to an immobilon membrane, and detected by immunoblotting with the same NFκB-
p65 (αp65) antibody to detect the levels of p65 in the precipitate, and with an anti acetylated-
Lysine specific antibody to detect the levels of acetylated p65 (αAc.p65) in the precipitate. The 
densitometric analysis shows the ratio between acetylated p65 amount and total p65 
immunoprecipitated amount, from three independent experiments (mean ± S.D).  . 
 
FIG. 7. A238L inhibits NFκB-p65 transactivation. Raw-pcDNA (grey bars) and Raw-A238L 
(black bars) cells were cotransfected with GAL4-p65 (50 ng DNA/106 cells) and GAL4-luc 
(150 ng DNA/106 cells) and cultured with 1 µg/ml of LPS plus 200 U/ml of IFN-γ (LPS/IFN-γ). 
At the indicated post-stimulation times, whole-cell extracts were prepared and luciferase activity 
was assayed. Extracts were normalized to Renilla luciferase activity as described in 
Experimental Procedures. Relative light units (RLU) per µg of protein from triplicate 
transfections (mean ± S.D.) are shown. 
 
FIG. 8. A238L inhibits the transactivation mediated by p300. Raw-pcDNA (grey bars) and 
Raw-A238L (black bars) cells were cotransfected with GAL4-p300 (50 ng DNA/106 cells) and 
GAL4-luc (150 ng DNA/106 cells) and cultured with 1 µg/ml of LPS plus 200 U/ml of IFN-γ 
(LPS/IFN-γ). Whole-cell extracts were prepared at the indicated post-stimulation times and 
luciferase activity was assayed. Extracts were normalized to Renilla luciferase activity as 
described in Experimental Procedures. Relative light units (RLU) per µg of protein from 
triplicate transfections (mean ± S.D.) are shown. 
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